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CDK6 is an oncogenic kinase regulating the cell cycle. In this issue of Cancer Cell, Kollmann and colleagues
demonstrate that CDK6 performs a kinase-independent transcriptional function in regulating expression of
VEGF-A and p16INK4a. These observations link the cell cyclemachinery and angiogenesis and reveal the pres-
ence of a fail-safe antiproliferative mechanism.Uncontrolled cell proliferation is a hall-
mark of cancer. Many cellular oncogenes
have been shown to promote cell prolifer-
ation by affecting a variety of signaling
pathways that impinge on the G1/S pro-
gression of the cell cycle. Similarly, com-
ponents of the cell cycle machinery are
subject to genomic alterations, point
mutations, or epigenetic modifications in
human cancers. Among those, genes
encoding D-type cyclins (D1, D2, and
D3) and their kinase partners (CDK4 and
CDK6) are frequently amplified and over-
expressed in many cancer types. More-
over, the inhibitor of cyclin D-CDK4/6
kinases, p16INK4a (together with p14ARF),
represents the most frequently deleted
locus across all human cancer types
(Beroukhim et al., 2010). Therefore, it is
currently well accepted that deregulated
cyclin D-CDK4/6 kinase activity repre-
sents a driving force in neoplasia. Inhibi-
tors of CDK4 and CDK6, PD0332991,
LEE011, and LY2835219 have entered
the clinics and are being used in cancer
trials. The initial results are very prom-
ising. Thus, it was recently reported
that treatment with PD0332991 greatly
extended progression-free survival in
women with advanced estrogen recep-
tor-positive breast cancer.
At the molecular level, cyclin D-CDK4/6
complexes drive cell proliferation by at
least two distinct mechanisms. During
cell cycle progression, CDK4 and CDK6
kinases phosphorylate the retinoblas-
toma protein (pRB) and pRB-related
p107 and p130 proteins. Phosphorylation
of these proteins leads to liberation or de-
repression of E2F transcription factors,
which then induce genes necessary for
S-phase entry and progression (Figure 1).Furthermore, cyclin D-CDK4/6 com-
plexes phosphorylate transcription fac-
tors, such as SMAD2/3 and FOXM1. In
addition to these kinase-dependent roles,
cyclin D-CDK4/6 complexes also bind to
the CDK inhibitors p21Cip1 and p27Kip1
and sequester them away from cyclin
E-CDK2 kinase. This leads to activation
of the cyclin E-CDK2 kinase activity,
which further promotes cell cycle pro-
gression by phosphorylating a wide range
of cellular proteins (Figure 1).
Genetic experiments revealed that
knockout mice devoid of Cdk4 or Cdk6
are viable and develop relatively normally,
indicating that these proteins are dis-
pensable for normal proliferation of the
majority of cell types (Malumbres et al.,
2004). Some specific compartments,
however, displayed proliferative deficits,
consistent with a positive, growth-pro-
moting function for Cdk4 and Cdk6.
Importantly, Cdk4- and Cdk6-null mice
were shown to be resistant to specific
cancer types (e.g., Hu et al., 2009). More-
over, acute ablation of Cdk4 or acute
inhibition of Cdk4/6 kinase activity in
mouse cancer models blocked the pro-
gression of cancers and leukemias by
triggering cancer cell senescence or
apoptosis (Puyol et al., 2010; Choi et al.,
2012; Sawai et al., 2012). All these obser-
vations firmly established CDK4 and
CDK6 as growth-promoting proteins.
The study by Kollmann et al. (2013),
published in this issue of Cancer Cell,
reveals several novel and unexpected
roles for CDK6. The authors show that,
contrary to what one might expect from
a positive regulator of the cell cycle
engine, overexpression of CDK6 inhibits
cell cycle progression and proliferationCancer Cell 24of BCR-ABL-transformed B cell leuke-
mia/lymphoma cells. Consistent with this
observation, the authors demonstrate
that CDK6 overexpression delays tumor
formation upon injection of leukemic cells
into recipient mice, indicating that CDK6
can act to constrain cell proliferation
in vivo. The authors explain this antiproli-
ferative function of overexpressed CDK6
by demonstrating that CDK6 induces
high levels of p16INK4a, an inhibitor of
CDK4/6 kinase and an inducer of cell
cycle arrest (Figure 1, left). In contrast, in
a mouse model of T cell lymphoma in
which p16INK4a is inactivated by promoter
methylation, CDK6 performs its known
growth-promoting function. This impli-
cates that in order to fulfill its oncogenic
role, overexpressed CDK6 requires can-
cer cells to silence p16INK4a (Figure 1,
right). Consistent with this prediction,
Kollmann et al. (2013) observed an inverse
correlation between CDK6 and p16INK4a
levels in human B cell and T cell lym-
phomas. Thus, induction of p16INK4a by
CDK6 serves as a fail-safe mechanism
that restricts excessive activity of CDK6
by forming a negative feedback loop.
The second lesson from the study by
Kollmann et al. (2013) is that CDK6, in
addition to its cell cycle role, can also
control the formation of blood vessels in
lymphoid tumors. The authors demon-
strate that overexpressed CDK6 induces
the transcription of vascular endothelial
growth factor A (VEGF-A), a known angio-
genic factor that stimulates the formation
of new blood vessels by endothelial cells.
This unexpected observation reveals that
overexpressed CDK6 can both drive cell
cycle progression (in the absence of
p16INK4a) and induce angiogenesis,, August 12, 2013 ª2013 Elsevier Inc. 141
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Figure 1. Model of the Function of CDK6 as Regulator of Cell Cycle and Angiogenesis
The regulation of cell cycle and proliferation by CDK6 depends on the functionality of the p16INK4a protein. CDK6 overexpression can either cause cell cycle arrest
in a cell with functional p16INK4a by activating p16INK4a transcription in a kinase-independent manner (left) or promote cell cycle progression if p16INK4a function is
lost (right). In addition to regulating cell cycle, CDK6 also induces angiogenesis by activating the transcription of VEGF-A, a known angiogenic factor, in a kinase-
independent manner.
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Previewsthereby linking two hallmark cancer
features. The combined promotion of
cellular proliferation and angiogenesis
resembles the characteristics of some
other known oncogenes, most notably
c-Myc (Dews et al., 2006). It remains to
be seen whether CDK6 also plays a pro-
angiogenic role in nonlymphoid tumors
and whether other CDKs (possibly
CDK4) might also perform such a function
in other tumor types.
Intriguingly, the authors demonstrate
that the upregulation of p16INK4a and
VEGF is caused by a direct, kinase-
independent, transcriptional mechanism
played by CDK6. Specifically, CDK6 is
shown to bind to p16INK4a and VEGFA
promoters and to activate their expres-
sion through interactionwith specific tran-
scription factors (Figure 1). Earlier studies
demonstrated that D-type cyclins play
kinase-independent roles in transcription
by acting on gene promoters. D-type
cyclins were shown to interact with
sequence-specific transcription factors,
such as STAT3 (Bienvenu et al., 2001),
and to help recruit chromatin-modifying
enzymes, thereby influencing gene
expression (Fu et al., 2004). Consistent
with these findings, Kollmann et al.
(2013) detected the presence of cyclin
D2, together with CDK6, at p16INK4a and
VEGFA promoters. Moreover, the tran-
scriptional activation of p16INK4a by142 Cancer Cell 24, August 12, 2013 ª2013 ECDK6 requires the presence of D-type
cyclins and depends on transcription fac-
tor STAT3. In contrast, induction of VEGF-
A transcription does not require D-type
cyclins and operates via AP-1 family tran-
scription factor c-Jun. It remains to be
seen whether another protein brings
CDK6 to the transcriptional machinery in
this setting or, alternatively, CDK6 inter-
acts directly with c-Jun. The involvement
of CDK6 in controlling transcription
without D-type cyclins is unexpected,
because, previously, transcriptional func-
tions were ascribed to D-type cyclins, but
not to their CDK partners. However,
a report has proposed a transcriptional
function for CDK6 in regulating an-
drogen-dependent expression of pros-
tate specific antigen (Lim et al., 2005).
Another unexpected outcome of the
current study is that the observed roles
for CDK6 are not shared by a closely
related kinase, CDK4. CDK4 and CDK6
display a high degree of homology and
are thought to act in a largely redundant
fashion. It remains to be seen whether
CDK4 can also perform cyclin D-indepen-
dent transcriptional functions, perhaps
by acting at different sets of promoters.
Global approaches, such as ChIP-Seq,
will allow the comparison of the interac-
tion of CDK4, CDK6, and D-type cyclins
with the genome in an unbiased,
genome-wide fashion.lsevier Inc.Currently, the roles of CDK4 and CDK6
in human cancer are believed to bemainly
kinase dependent, a notion that led to the
development of specific CDK4/6 inhibi-
tors that are now in clinical trials. These
inhibitors are expected to inhibit the prolif-
erative function of CDK4/6 complexes,
leading to cell cycle arrest and potentially
triggering senescence or apoptosis. How-
ever, the novel kinase-independent role of
CDK6 in promoting angiogenesis sug-
gests that a new class of CDK4/6 inhibi-
tors capable of interrupting the angio-
genic function, in addition to blocking
the proliferative role of CDK6, might be
clinically more successful. These inhibi-
tors might also be useful in pRB-deficient
tumors, in which CDK6 inhibition is not
expected to affect cell proliferation.ACKNOWLEDGMENTS
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Inflammation is increasingly recognized as an essential component of tumor development, but the origin
of tumor-associated inflammation remains largely unknown. In this issue of Cancer Cell, Pribluda and
colleagues find that chronic stress initiates senescence-inflammatory response, which can promote tumor-
igenesis in the absence of exogenous inflammatory triggers.Cellular senescence may be compared
to a differentiation program because of
its dramatic effects on cell morphology,
metabolism, and chromatin structure.
Yet, physiological roles of senescence
remain poorly understood.
Because senescence induces perma-
nent cell cycle arrest, it is thought to func-
tion to suppress tumor development
(Rodier and Campisi, 2011). However,
it is unclear why senescence is used
instead of apoptosis, which would perma-
nently eliminate oncogenic cells. The phe-
nomenon of cell senescence is, in many
ways, analogous to T cell anergy, where
autoreactive and potentially harmful
T cells are rendered unresponsive to
stimulation. Why anergic and apparently
unwanted T cells are not eliminated by
apoptosis remains unknown. Likewise
it is unclear why senescent cells are
retained rather than eliminated.
One possible clue to this puzzle is that,
in addition to cell cycle arrest, senescent
cells may have non-cell-autonomous
roles based on their secretory activity.
Indeed, senescence-associated secre-
tory phenotype (SASP) is a common
feature of senescent cells (Rodier and
Campisi, 2011). They primarily releaseproinflammatory cytokines, chemokines,
and extracellular-matrix remodeling fac-
tors. Many of these proteins are critical
in promoting tissue repair and can be
produced in larger quantities by macro-
phages in response to infection or
damage.
The view of senescence as a form of
tissue repair response may explain
another paradox of cell senescence; in
some contexts, it has a tumor-promoting
effect. Tumor growth has features of
deregulated tissue repair, but what
initiates this repair response is unclear.
Tissue repair accompanies the inflamma-
tory response induced by tissue injury.
However, how these responses are
induced in tumors remains poorly under-
stood despite increasing appreciation of
their critical role in tumor development
(Ben-Neriah and Karin, 2011).
The article by Pribluda et al. (2013) in
this issue of Cancer Cell establishes new
functional links between tissue stress,
senescence, low-grade inflammatory
response, and tumor progression. To
introduce these findings, we first need to
address the terminology of senescence
and inflammation, which is often inconsis-
tent and even confusing.By being implicated in diverse biolog-
ical processes, both ‘‘senescence’’ and
‘‘inflammation’’ have been stretched far
beyond their original definitions, often
creating challenges in use and interpreta-
tion. Senescence is often defined by an
arbitrary number of optional markers, pre-
dominantly phenotypic and not always
present together. Every single hallmark
of senescence has been found dispens-
able for at least some of the senescence
states described. Even permanent growth
arrest, the most definitive feature of
senescence, can be missing in some
cases. For example, senescent hemato-
poietic stem cells defined in physiological
aging or genotoxic stress display multiple
senescent markers while retaining partial
proliferative capacity (Chen, 2011).
Because of this vague terminology,
senescence phenotypes reported in
different studies sometimes show little
overlap.
Similarly, ‘‘inflammatory responses’’
differ greatly depending on the nature
of the inducer, responding cells, etc.
Both senescence and inflammation are
induced by stress and share some com-
ponents. Not surprisingly, what is defined
as a senescence response in one setting, August 12, 2013 ª2013 Elsevier Inc. 143
